A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
ConditionArthritis, Rheumatoid
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Eligibility criteria
Qualifiers
None
Disqualifiers
Juvenile arthritis or onset of inflammatory arthritis before age 18.
Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.
Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.
Other protocol-defined Inclusion/Exclusion criteria apply.
Trial design
Treatments tested in this trial
- BMS-986528
Treatment groups
84 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov